PainReform Ltd. (PRFX) Stock

PainReform Ltd., a clinical-stage specialty pharmaceutical company headquartered in Tel Aviv, Israel, specializes in developing therapeutics aimed at delivering prolonged post-surgical pain relief. At the forefront of its product development is PRF-110, an innovative viscous clear oil-based solution. This solution is strategically administered directly into the surgical wound, offering localized and extended analgesic effects following surgical procedures.

Currently, PainReform Ltd. is actively advancing PRF-110 through two pivotal Phase 3 clinical trials. These trials specifically target patients undergoing bunionectomy surgery and hernia repair, assessing the efficacy and safety of PRF-110 in these clinical settings. The company's commitment to addressing unmet medical needs underscores its mission to enhance post-operative recovery outcomes through innovative pain management solutions.

Founded in 2007, PainReform Ltd. continues to drive forward with its dedication to advancing therapeutic options in pain management.v. With a strong emphasis on clinical research and development, the company aims to establish PRF-110 as a transformative treatment option in the field of surgical pain relief.